Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ELMD 
Electromed Inc (ELMD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/03/2025: ELMD (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $36
1 Year Target Price $36
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 44.56% | Avg. Invested days 35 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 12/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 234.11M USD | Price to earnings Ratio 29.73 | 1Y Target Price 36 |
Price to earnings Ratio 29.73 | 1Y Target Price 36 | ||
Volume (30-day avg) 1 | Beta 0.27 | 52 Weeks Range 17.73 - 35.56 | Updated Date 12/3/2025 |
52 Weeks Range 17.73 - 35.56 | Updated Date 12/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.94 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-11 | When - | Estimate 0.21 | Actual 0.25 |
Profitability
Profit Margin 12.38% | Operating Margin (TTM) 15.81% |
Management Effectiveness
Return on Assets (TTM) 12.93% | Return on Equity (TTM) 19.02% |
Valuation
Trailing PE 29.73 | Forward PE 25.91 | Enterprise Value 212999849 | Price to Sales(TTM) 3.54 |
Enterprise Value 212999849 | Price to Sales(TTM) 3.54 | ||
Enterprise Value to Revenue 3.22 | Enterprise Value to EBITDA 18.36 | Shares Outstanding 8340538 | Shares Floating 6575847 |
Shares Outstanding 8340538 | Shares Floating 6575847 | ||
Percent Insiders 21.07 | Percent Institutions 53.01 |
Upturn AI SWOT
Electromed Inc
Company Overview
History and Background
Electromed, Inc. was founded in 1980. It focuses on developing, manufacturing, and marketing airway clearance technologies. The company's primary product is the SmartVest Airway Clearance System.
Core Business Areas
- Airway Clearance Systems: Development, manufacturing, and marketing of the SmartVest system for patients with compromised airway clearance due to cystic fibrosis, bronchiectasis, and other respiratory conditions.
Leadership and Structure
Kathleen Skarvan serves as President and CEO. The company has a typical corporate structure with departments like sales, marketing, R&D, manufacturing, and finance.
Top Products and Market Share
Key Offerings
- SmartVest Airway Clearance System: The SmartVest system uses High-Frequency Chest Wall Oscillation (HFCWO) technology to loosen and thin mucus in the lungs, making it easier to cough up. The company estimated that 25% of the market is owned by Electromed. Competitors include Hill-Rom, RespirTech, and Philips Respironics.
Market Dynamics
Industry Overview
The airway clearance market is driven by the increasing prevalence of chronic respiratory diseases like cystic fibrosis and bronchiectasis. Demand is also fueled by advancements in airway clearance technologies.
Positioning
Electromed is a key player in the HFCWO segment of the airway clearance market, recognized for its SmartVest technology. The company differentiates itself by focusing on patient comfort and ease of use.
Total Addressable Market (TAM)
The global airway clearance systems market size was valued at USD 1.3 billion in 2023 and is expected to reach USD 1.9 billion by 2032. Electromed is positioned to capture a portion of this growth, expanding its market share with its SmartVest system.
Upturn SWOT Analysis
Strengths
- Established brand recognition in HFCWO segment
- Focus on patient comfort and ease of use
- Strong intellectual property protection
- Direct sales force
Weaknesses
- Limited product portfolio compared to larger competitors
- Reliance on Medicare and private insurance reimbursement
- Smaller market capitalization compared to competitors
Opportunities
- Expanding into new geographic markets
- Developing new products and services for respiratory care
- Increasing awareness of HFCWO therapy
- Partnerships with healthcare providers and patient advocacy groups
Threats
- Competition from larger medical device companies
- Changes in reimbursement policies
- Technological advancements by competitors
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- VHC
- PHG
- RDMD
Competitive Landscape
Electromed competes with larger medical device companies with broader product portfolios. Electromed's advantage lies in its specialized focus on HFCWO therapy and its established brand recognition.
Growth Trajectory and Initiatives
Historical Growth: Electromed has experienced steady revenue growth over the past few years, driven by increased adoption of its SmartVest system.
Future Projections: Analysts project continued revenue growth in the coming years, driven by expanding market share and increasing awareness of HFCWO therapy.
Recent Initiatives: Electromed has been focusing on expanding its sales force and marketing efforts to reach new patient populations. The company is also investing in R&D to develop new and improved products.
Summary
Electromed Inc. is a stable company in the airway clearance market, known for its SmartVest system and focus on patient comfort. The company benefits from consistent revenue growth and a healthy financial position. However, it faces competition from larger companies and relies on reimbursement policies. Continued growth will depend on expanding market share and new product development.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings (10-K, 10-Q)
- Analyst reports
- Industry publications
- Company website
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Market data and analyst estimates are subject to change. Past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Electromed Inc
Exchange NYSE MKT | Headquaters New Prague, MN, United States | ||
IPO Launch date 2010-08-13 | President, CEO & Director Mr. James L. Cunniff | ||
Sector Healthcare | Industry Medical Devices | Full time employees 177 | Website https://smartvest.com |
Full time employees 177 | Website https://smartvest.com | ||
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy, muscular dystrophies, amyotrophic lateral sclerosis, and post-surgical complications; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.